

---

# 41. RESPIRATORY INFECTION IN IMMUNOCOMPROMISED NEUTROPENIC PATIENTS

---

Stephen W. Crawford

## *Scope of Problem*

Neutropenia is increasingly common in the hospital. The rise in incidence is due to proliferation of indications for and centers performing hematopoietic stem cell transplantation, hematologic effects of AIDS, and myelosuppressive side-effects of anti-viral and cancer chemotherapies [Table 1]. As a result, these neutropenic patients are increasingly common in ICUs. These patients are often lymphopenic, anemic, and thrombocytopenic. They are at risk for multiple organ failures and various infections. This chapter will focus on respiratory infections in the neutropenic patient.

## *Neutropenia and the Risk Factor for Infection*

The neutrophil plays a key role in host defense of extracellular bacteria (especially encapsulated organisms affected by opsonizing antibodies) and the molds and yeasts. The incidence of serious infection in neutropenic patients increases with the depth, rapidity of onset, and duration of neutropenia. The risk of infection increases with an absolute neutrophil count (ANC)  $<1000$  cells/mm<sup>3</sup>, and is significantly higher with an ANC  $<500$  cells/mm<sup>3</sup>. A rapid decline in ANC and duration of neutropenia  $>7$  to 10 days is associated with increase in serious, life-threatening infection. Likewise, morbidity

and mortality are increased in patients with profound neutropenia (ANC  $<100$ /mm<sup>3</sup>) [1–3].

A study of severe, short-duration neutropenia demonstrates that fungal infections are rare when the ANC is reduced for less than five days. Neutropenic fever developed in 94% of patients after peripheral stem cell transplantation [4]. Profound neutropenia was short-lived (average five days) and most patient's fever defervesced in median of four days. Although bacteremia developed in 39% (predominately Gram-positive cocci), only 5% had pulmonary infiltrates and there were no fungi identified and no infection-related deaths.

Neutrophil function before chemotherapy to treat leukemia influences infection rates [5]. Patients with a significant decrease in phagocytic activity of neutrophils developed more severe infection or died more often compared to those with no infection. Study of the neutrophil oxidative burst capacity suggested that the neutrophils may have been pre-activated and have reduced function prior to the initiation of chemotherapy.

Neutropenia associated with myelosuppression, as occurs after chemotherapy, rarely occurs in isolation from other defense defects. Lymphopenia, decreased humoral immunity, and mucosal barrier defects invariably contribute to the defense abnormalities that predispose to infection in these settings.

TABLE 1. Some causes of neutropenia

---

● Drug myelosuppression
○ Chemotherapy
○ Ganciclovir
○ Trimethaprim-sulfamethoxazole
● Viral infection
○ Late stages of AIDS
○ Herpes viruses
● Congenital deficiency
○ Inherited cyclic neutropenia
● Functional defects
○ Corticosteroids
○ Chediak-Higashi syndrome
○ Myeloperoxidase deficiency
○ Chronic granulomatous diseases

---

Both tumors and chemotherapy contribute to infection among neutropenic patients. Obstruction of the lymphatic, biliary tract, gastrointestinal or urinary systems by tumors or as a result of surgical procedures is a common cause of infections. Chemotherapy not only decreases the number of neutrophils, but also results in chemotactic and phagocytic defects. Chemotherapy, radiation, peripheral and central intravenous lines, surgery, or tumor invasion can induce breakdown of skin and mucosal barriers and can result in bacteremia. Mucositis may occur throughout the gastrointestinal system. Translocation of endogenous flora in the GI tract may explain a majority of febrile neutropenic episodes.

### *Trends in Infection in the Neutropenic Patient*

Historically, Gram-negative bacilli, particularly *P. aeruginosa*, were the most commonly identified pathogens. Data from several sources attest to a decrease in the incidence of pseudomonal bacteremia and an increase in Gram-positive infections. The use of long-term indwelling lines accounts for some of the appearance of Gram-positive infections; the empiric antibiotic regimens that were designed to cover *P. aeruginosa*

may be an additional factor. For example, the incidence of bacteremia due to Gram-negative bacilli in Japan decreased (40% to 64%) and infections due to Gram-positive bacteria increased (51% to 24%) in 1991 to 1996 compared to the prior 15 years [6].

In the last decade there has been an increasing incidence of Gram-positive cocci infection in the neutropenic population. Foremost among these organisms are viridans streptococci, vancomycin-resistant enterococci, and coagulase-negative staphylococci. In addition, there is an alarming trend toward increasing fungal infections. Notably, reports of *Candida* species isolates are up 20-fold since the 1980s. *Aspergillus* reports have increase 14-fold. In addition, the number of "unusual" fungal species (*Trichosporon*, *Fusarium*, *Mucor*) has also increased.

Importantly, there has been an alarming increase in the frequency of antibiotic resistant organisms isolation. These pathogens include coagulase-negative staphylococci, methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), and penicillin (ceftriaxone)-resistant *S. pneumoniae*.

### *Sites and Causes of Infections*

Mortality in the febrile, neutropenic population is high, in the range of 30 to 50 per cent. Early studies of empiric antibiotics in febrile neutropenia suggested that a majority of patients had occult bacterial infections. However, an infectious source is identified in only approximately 30 per cent of febrile neutropenic episodes. Often the only evidence of infection is bacteremia, which occurs in over 20 per cent of patients. Approximately 80 per cent of identified infections are believed to arise from patient's own endogenous flora. The most commonly identified sources of infection in febrile neutropenic patient with leukemia are the perineal and perirectal areas, followed by the urinary tract, skin (including intravenous lines and wounds) and the lungs. However, among non-

hematopoietic cancer patients pulmonary infections predominate. Many infections are detected only at autopsy, particularly disseminated fungal or combined fungal and bacterial infections.

There are numerous infections that cause pneumonia in cancer patients [7–9]. Typical bacteria are most common, accounting for over one-third of infections. Fungi, viruses, *Pneumocystis carinii* (PCP), *Nocardia asteroides*, and *Mycobacterium tuberculosis* account for a measurable number of cases each. Compounding the difficulty in establishing an etiologic agent, mixed infections may be present in up to 20 per cent of cases.

Evidence suggests that fungal infection is a common component of neutropenic fever after chemotherapy. Pneumonia tends to develop several days after the onset of fever. Only 27% of febrile neutropenic patients with pneumonia respond without addition of anti-fungal agents. Over half of documented lower respiratory infections are due to fungi. Therefore, it is not surprising that the prognosis is worse for febrile neutropenic patients who develop pneumonia.

Noninfectious etiologies are common for immunocompromised patients with pulmonary infiltrates. Causes include pulmonary embolus, tumor, radiation pneumonia, atelectasis, pulmonary hemorrhage, and drug allergy or toxicity. Aspiration remains an important source of pulmonary infection in all compromised patients.

### *Bacterial Pathogens*

*Viridans streptococci* (both *mitis* and *sanguis*) have become of major concern in the neutropenic host. These organisms are associated with 39% of neutropenic bacteremia after chemotherapy [10]. The complications associated with these organisms are: ARDS, shock, and endocarditis. An ANC <100/mm<sup>3</sup> is among the strongest risk factors.

Institutional infection patterns impact the frequency and type of organisms isolated and

a variety of nosocomial outbreaks in cancer patients have been reported. Some centers have reported an increased incidence of resistant pathogens such as *Candida krusei* with the routine use of prophylactic antibiotics and antifungals [11, 12]. Antibiotic history, recent culture results, exposure to prophylactic antibiotics, and the susceptibility patterns for organisms in the institution should be used to help guide selection of initial antibiotic therapy.

### *Fungal Pathogens*

Fungal infections probably represent the greatest infectious risk to neutropenic patients. Fungal infections are common among neutropenic patients, and usually arise after prolonged neutropenia and antibiotic use. Empiric antibiotics promote oral and vaginal colonization with yeast, most commonly *Candida albicans*. Hepato-splenic involvement is common in patients with disseminated candidiasis after chemotherapy. Often, symptoms are absent until the neutropenia resolves. Current diagnostic tests lack sufficient sensitivity to distinguish invasive yeast infection from colonization [13].

The incidence of nosocomial candidal infections continues to rise in the United States, and *C. albicans* is the most commonly identified species. Candidal infections are associated with the highest mortality rates of all hospital-acquired bloodstream infections, with substantial related increases in hospital costs, particularly length of stay. The three most common pathogens causing nosocomial bloodstream infections in US hospitals are cocci: coagulase-negative staphylococci, 31.9% of isolates; *Staphylococcus aureus*, 15.7%; and Enterococci, 11.1%. According to these Surveillance and Control of Pathogens of Epidemiologic Importance Program data from 1995–1998 the fourth most common pathogens were *Candida* species, representing 7.6% of all isolates [14]. Clearly, *Candida* species are increasing in importance in the ICU as well. According to recent data from Pfaller *et al.*, *Candida*

*albicans* accounts for just over half of candidal species isolated. *C. tropicalis*, *C. glabrata*, and *C. parapsilosis* contribute 44% of isolates [15]. Speciation is important since *C. tropicalis* and *C. krusei* are resistant to fluconazole, the agent more commonly used to treat yeast infection in the ICU. The crude mortality associated with these pathogens increases with decreasing prevalence. Mortality with the most common, coagulase-negative staphylococci, is 21% and rises to 40% with the *Candida* species infections. The mortality attributable to *Candida* has been estimated at 70–88% [16, 17]. Diagnosis of candidiasis in the neutropenic host should be considered an indication for urgent therapy. The death rates among neutropenic patients with candidiasis are as high 24% with a week of diagnosis and 63% within three months [18]. Although lower among patients without neutropenia, the rates are still high.

*Candida* is a common infection among neutropenic patients but a rare cause of pneumonia. Haron *et al.* reported that there were only 31 cases documented at autopsy over 20 years at the MD Anderson Cancer Center [19]. The clinical and radiographic presentation of these cases was that of bronchopneumonia. There were no distinguishing features of the infection to identify the organism. Of note, most of the patients were not neutropenic at time of onset of pneumonia.

Candidiasis is rare in the absence of colonization of the skin, rectum or throat. Gut translocation may account for a substantial proportion of cases. The major threat to life is associated with disseminated, invasive candidiasis. Candidal invasion is associated with identified risk, and thus these are also risks for mortality. The reported risks include:

- Use of three or more antibiotics
- Neutropenia
- Immunosuppression (due to cancer/chemotherapy, steroids, other therapies)
- Concomitant infection
- Spending more than four days in ICU
- Mechanical ventilation >48 hours
- An elevated APACHE II score
- Abdominal surgery
- Central venous catheterization
- Total parenteral nutrition (TPN)
- Diabetes mellitus
- *Candida* colonization of more than 3 sites
- Candiduria (>100,000 colonies/ml)
- Thrush

The therapeutic choices for treatment of systemic candida infections include fluconazole, conventional amphotericin B, liposomal amphotericin B, and lipid-complex amphotericin B. All of these are available intravenously. Only fluconazole is available orally, however this is rarely an issue in the ICU population. Fluconazole has been shown recently to be comparable to conventional amphotericin b for treatment of candidemia in patients without neutropenia [20]. In this study, fluconazole was associated with less renal dysfunction, hypokalemia, and lower liver enzymes than amphotericin B. It is likely that the same pattern of efficacy and toxicity would be found among neutropenic patients.

Infections with molds, such as *Aspergillus* sp, vary from localized skin ulcers and invasive pneumonia, to fulminant disseminated disease. *Fusarium* sp. infections have been increasingly reported in immunocompromised host [21–25]. Reactivation of endemic fungi (histoplasmosis, blastomycosis, and coccidioidomycosis) or tuberculosis mimics the radiographic presentation of invasive fungal pneumonia and should be considered in appropriate patients with prolonged steroids or immune suppression.

Kaiser *et al.* recently reviewed the clinical presentations of invasive pulmonary aspergillosis (IPA) in a study of 35 confirmed cases [26]. The diagnosis of IPA was not suspected in 40% of the cases. The lungs were involved in 94% and the infection was limited to lungs in 74%. Other sites of infection were the heart, CNS, liver, spleen, and skin. Only 40% were neutropenic at the time of diagnosis but 91% had used steroids in the recent past. Of importance to the management of IPA, concurrent infections were

found in 83% of cases. The mortality rate was 94%.

### *Viral Pathogens*

Viral infections, especially human herpes viruses, are common in the neutropenic population. However, neutropenia *per se*, is not the primary risk factor for viral infection. Cell-mediated immunity (CMI) is the most important host defense against most respiratory viral pathogens. Since many patients with neutropenia also have concomitant defects in CMI they are at risk. Herpes simplex viruses, HSV-1 and HSV-2, while common causes of skin eruptions, can also cause a wide variety of clinical syndromes, including: encephalitis, meningitis, myelitis, esophagitis, pneumonia, hepatitis, erythema multiforme, and ocular syndromes. Immunocompromised patients with disseminated varicella zoster virus (VZV) infection can have pulmonary involvement and should be placed on respiratory precautions to prevent aerosolized transmission to susceptible individuals. Cytomegalovirus remains a significant cause of diffuse pneumonia and respiratory failure among transplant recipients.

Of great concern is the emergence of respiratory viral infections including Respiratory Syncytial Virus (RSV) as significant causes of nosocomial pneumonia. Outbreaks of infection resulting in diffuse pneumonia and respiratory failure have been reported among severely myelosuppressed patients after chemotherapy [27]. These infections should be suspected during winter and spring months, if there is associated airflow obstruction, or if upper respiratory tract symptoms preceded the onset of infiltrates. Many outbreaks reported appear to have been nosocomial. Visitors and hospital staff are likely responsible for transmission of the virus. Prompt treatment with ribavirin (with or without immunoglobulin) has been reported as beneficial. There are few data from large series to support that these are effective treatments in severely ill neutropenic patients.

### *Radiographic Diagnosis*

The radiographic appearance of pneumonia in the neutropenic patient carries important diagnostic information as to the possible etiology of infection. A focal or multifocal consolidation of acute onset is most commonly caused by a bacterial infection. However, similar multifocal lesions with a subacute to chronic progression may be due to fungal, tuberculous, or nocardial infections. Large nodules are usually a sign of fungal or nocardial infection in this patient population, particularly if they are subacute to chronic in onset. Viruses (especially CMV) or *P. carinii* usually cause subacute disease with diffuse abnormalities, either peribronchovascular or small miliary nodules. The presence of cavitation suggests a necrotizing infection that can be caused by fungi, *Nocardia*, and certain Gram-negative bacilli (most commonly *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*) [8].

Chest computed tomography of the chest can help to assess the extent of the disease process and more completely define its characteristics. The morphology of the abnormalities found on CT scan can also be very useful in developing a differential diagnosis in the individual patient. Cavitory mass lesions are suggestive of infections with *Nocardia*, *Cryptococcus*, or invasive fungus, such as *Aspergillus*. The invasive fungal pneumonias classically develop cavitation and a surrounding zone of radiographic attenuation. This zone is presumably due to associated edema and hemorrhage. However, this finding is non-specific. Any process or infection resulting in lung infarction can yield similar CT findings (Table 2) [28]. In contrast, dense regional or lobar consolidation on CT is suggestive of bacterial pneumonia.

Chest CT scanning may identify the site for optimal sampling and assist in defining the most appropriate invasive procedure. Thus, CT can provide precise guidance for needle biopsy or for thoracoscopic or open lung excision in the case of peripheral lung nodules [29, 30]. CT can also

TABLE 2. Radiographic mimics of invasive pulmonary Aspergillosis

- 
- *Mucor*, *Fusarium*, *Scedosporium*, etc.
  - Legionella
  - Nocardia
  - Rhodococcus
  - Gram-negative enterics
  - Pulmonary embolism
  - BOOP
- 

help to predict whether bronchoscopy is likely to be useful. As an example, the demonstration of a feeding bronchus in association with a pulmonary nodule greatly increases the diagnostic yield when bronchoscopy is performed (60 versus 30 per cent when the feeding bronchus is not visible). If CT demonstrates centrally located diffuse opacifications, a bronchoscopic approach is the procedure of choice.

### Treatment

**Antibacterial drugs.** None of the numerous antibiotic regimens studied as initial empiric therapy in febrile neutropenia have been shown to be clearly superior. The majority of the tested regimens provide coverage targeted at Gram-negative bacilli, especially *P. aeruginosa*. The most common empiric treatment approaches include either “monotherapy” (with agent such as, ceftazidime, imipenem, meropenem, or cefepime) or “double coverage” (with a beta-lactam and an aminoglycoside, or double beta-lactams).

Double beta-lactams are generally avoided due to the concern of overlapping toxicities. However, double coverage with the aztreonam and a beta-lactam in patients unable to tolerate an aminoglycoside may be a reasonable alternative. Two drug regimens for empiric therapy of febrile neutropenia are widely used. Clinical trials with monotherapy, either ceftazidime or imipenem cilastatin or meropenem, have demonstrated equal efficacy compared to two drug regimens [31, 32]. In one study treatment with meropenem was compared to ceftazidime in

187 patients; the number of patients on the therapy at 72 hours and the completion of treatment was equivalent between the groups (50% versus 56% and 46% versus 49%, respectively) [33]. However, changes in the antibiotic regimen are more common when monotherapy is used [2, 31].

The French Febrile Aplasia Study Group report is one of the few studies to show a difference in empiric antibiotic regimen [34]. The empirical use of a piperacillin/tazobactam and amikacin combination had superior response rates compared to ceftazidime and amikacin (48% versus 29%). Notably, the response rates to ceftazidime and amikacin decreased over time as the incidence of Gram-negative infections declined from 22% to 17.5%. The incidence of Gram-positive infections increased from 20% to 28%. This study provides increasing evidence of the fungal infection problem in neutropenic hosts. There was an increase in *Aspergillus*-related deaths (from 1.8% to 5.4%), while the overall infection-related mortality remained unchanged over time. It remains important to continue to monitor microbiology regardless of initial antibiotic choices.

Vancomycin is frequently considered in patients who present with hypotension, mucositis, skin or catheter site infection, a history of MRSA colonization, recent quinolone prophylaxis or persistent fever despite empiric antibiotics. However, addition of vancomycin to the initial empiric antibiotic regimen has not been shown to decrease mortality [2]. The addition of empiric vancomycin did not improve outcome among febrile neutropenic patients with skin and soft tissue infections despite a higher incidence of proven Gram-positive bacteremia compared to patients with other infections (31% versus 17%), [35].

**Antifungal drugs.** The incidence of fungal infection (especially *Candida* or *Aspergillus*) rises after patients have experienced more than seven days of persistent fever and neutropenia [36]. Antifungal therapy is routinely added at five to seven days of neutropenia in patients with

persistent fever. While amphotericin B has been used for empiric therapy the longest, there is growing experience with fluconazole and lipid formulations of amphotericin B. For example, in one study fluconazole prophylaxis reduced the number of and mortality from invasive fungal infections compared to placebo in one multicenter trial in Canada [37]. The effect was greatest in patients with acute myelogenous leukemia and those receiving autologous bone marrow; both groups received the most intensive chemotherapeutic regimens. Another small study found empiric fluconazole equivalent in outcome to amphotericin B (at the relatively low dose of 5 mg/kg per day) in neutropenic patients who remained febrile after one week of broad-spectrum antibiotics; adverse effects were higher in the amphotericin group [38].

Fluconazole is well tolerated but is ineffective against *Aspergillus* and some yeast (e.g., *C. krusei* and *C. glabrata*). A retrospective study of hematogenous candidiasis from the M. D. Anderson Cancer Center found a shift toward *C. krusei* and *C. glabrata* infection and away from *C. tropicalis* and *C. albicans*; fluconazole prophylaxis appeared to be significant in promoting this trend [39].

Fluconazole prophylaxis is frequently used in populations at risk for *Candida* infection, such as neutropenic chemotherapy or organ transplant recipients. A review of 355 autopsies after marrow transplantation detected a disturbing trend among those patients who received fluconazole prophylaxis [40]. The treatment was effective in decreasing both *Candida* infections (from 27% to 8%) and fungal liver infection (from 16% to 3%). However, *Aspergillus* infections increased from 18% to 29%. Duration of survival increased but overall mortality was unchanged. The authors surmised that the fluconazole prophylaxis increased duration of survival by decreasing early infection with *Candida* and thus, increased the exposure to *Aspergillus* infections.

Recent trials suggest that lipid formulations of amphotericin B are better tolerated and offer

similar efficacy. In one large randomized, multicenter trial, 343 neutropenic patients received liposomal amphotericin B (3 mg/kg per day) and 344 amphotericin B (0.6 mg/kg per day) as empiric therapy after at least five days of fever and broad-spectrum antibiotics [41]. The outcomes were comparable for the two therapies for overall success (50 versus 49 per cent), resolution of fever during neutropenia (58 versus 58 per cent), absence of documented fungal infection (90 versus 89 per cent), and cure of fungal infection (82 versus 73 per cent). The liposomal preparations were better tolerated than conventional amphotericin with fewer infusion related symptoms including rigors and less nephrotoxicity. However, these new forms of amphotericin are significantly more expensive. Recent studies suggest that itraconazole in daily dose of 200 mg to 400 mg also may be effective treatment for aspergillosis in patients refractory or intolerant to amphotericin B. Itraconazole is available both in oral and intravenous formulations. The precise role of this agent in the management of invasive fungal disease in the neutropenic ICU patient is undefined.

*Colony stimulating factors.* The role of colony stimulating factors (CSF) continues to expand. In some clinical settings, CSF has been reported to decrease the duration of neutropenia, fever and hospitalization [42–44]. However, CSF has not been shown to decrease mortality, and is not considered routine at this time [45]. It may be appropriate to consider their use in critically ill patients such as those with pneumonia, hypotension, or organ dysfunction or in patients whose bone marrow recovery is expected to be especially prolonged.

## References

1. Hathorn JW, Lyke K. Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Clin Infect Dis 24(Suppl 2): S256, 1997.
2. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323, 1993.

3. Rubin RH, Ferraro MJ. Understanding and diagnosing infectious complications in the immunocompromised host. *Current issues and trends. Hematol Oncol Clin North Am* 7:795, 1993.
4. Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. *Bone Marrow Transplant* 19:143, 1997.
5. Hubel K, Hegener K, Schnell R, *et al.* Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. *Ann Hematol* 78:73, 1999.
6. Funada H, Matsuda T. Changes in the incidence and etiological patterns of bacteremia associated with acute leukemia over a 25-year period. *Intern Med* 37:1014, 1998.
7. Ramsey PG, Rubin RH, Tolkoff-Rubin NE, *et al.* The renal transplant patient with fever and pulmonary infiltrates: Etiology, clinical manifestations, and management. *Medicine* 59:206, 1980.
8. Rubin RH, Greene R. Clinical approach to the compromised host with fever and pulmonary infiltrates. In Rubin RH, Young LS (eds). *Clinical Approach to Infection in the Compromised Host*, 3rd edn. New York: Plenum Press, 1994: 121.
9. Chanock S. Evolving risk factors for infectious complications of cancer therapy. *Hematol Oncol Clin North Am* 7:771, 1993.
10. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. *Clin Infect Dis* 18:25, 1994.
11. Goodman JL, Winston DJ, Greenfield RA, *et al.* A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. *N Engl J Med* 326:845, 1992.
12. Oppenheim BA. The changing pattern of infection in neutropenic patients. *J Antimicrob Chemother* 41:S7, 1998.
13. Sugar AM. Empiric treatment of fungal infections in the neutropenic host: review of the literature and guidelines for use. *Arch Intern Med* 150:2258, 1990.
14. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. *Clin Infect Dis* 29:239, 1999.
15. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of *Candida* species in the United States. *Diagn Microbiol Infect Dis* 33:217, 1999.
16. Digiiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. *Am J Respir Crit Care Med* 160:976, 1999.
17. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. *Clin Infect Dis* 15:414, 1992.
18. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. *Am J Med* 104:238, 1998.
19. Haron E, Vartivarian S, Anaissie E, Dekmezian R, Bodey GP. Primary *Candida* pneumonia. Experience at a large cancer center and review of the literature. *Medicine* 1993.
20. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, *et al.* A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. *N Engl J Med* 331:1325, 1994.
21. Richardson SE, Bannatyne RM, Summerbell RC, *et al.* Disseminated fusarial infection in the immunocompromised host. *Rev Infect Dis* 10: 1171, 1988.
22. Boutai EI, Anaissie EJ. *Fusarium*, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. *Blood* 90:999, 1997.
23. Krcmery V Jr, Kunova E, Jesenska Z, *et al.* Invasive mold infections in cancer patients: Five years' experience with *Aspergillus*, *Mucor*, *Fusarium* and *Acremonium* infections. *Support Care Cancer* 4:39, 1996.
24. Martino P, Gastaldi R, Raccach R, *et al.* Clinical patterns of *Fusarium* infections in immunocompromised patients. *J Infect* 28:7, 1994.
25. Walsh TJ, Hiemenz JW, Seibel NL, *et al.* Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. *Clin Infect Dis* 26:1383, 1996.
26. Kaiser L, Huguenin T, Lew PD, Chapuis B, Pittet D. Invasive aspergillosis. Clinical features



- of 35 proven cases at a single institution. *Medicine* 77:188, 1998.
27. Whimbey E, Couch RB, Englund JA, Andreeff M, Goodrich JM, Raad II, Lewis V, Mirza N, Luna MA, Baxter B, *et al.* Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. *Clin Infect Dis* 21:376, 1995.
  28. Won HJ, *et al.* Invasive pulmonary aspergillosis: Prediction at thin-section CT in patients with neutropenia – A prospective study. *Radiology* 208:777, 1998.
  29. Jamzen DL, Adler BD, Padley SPG, *et al.* Diagnostic success of bronchoscopic biopsy in immunocompromised patients with acute pulmonary disease: Predictive value of disease distribution as shown on CT. *Am J Roentgenol* 160:21, 1993.
  30. Scott WW, Kuhlman JE. Focal pulmonary lesions in patients with AIDS: Percutaneous transthoracic needle biopsy. *Radiology* 180:419, 1991.
  31. Pizzo PA, Hathorn JW, Hiemenz J, *et al.* A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. *N Engl J Med* 315:552, 1986.
  32. Cometta A, Calandra T, Gaya H, *et al.* Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. *Antimicrob Agents Chemother* 40:1108, 1996.
  33. Lindblad R, Rodjeer S, Adriansson M, *et al.* Empiric monotherapy for febrile neutropenia – A randomized study comparing meropenem with ceftazidime. *Scand J Infect Dis* 30:237, 1998.
  34. Marie JP, *et al.* Neutropenic infections: Review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. *J Antimicrob Chemo* 41(Suppl D):57, 1998.
  35. Dompeling EC, Donnelly JP, Deresinski SC, *et al.* Early identification of neutropenic patients at risk of gram-positive bacteraemia and the impact of empirical administration of vancomycin. *Eur J Cancer* 32:1332, 1996.
  36. Kibbler CC. Empirical antifungal therapy in febrile neutropenic patients: Current status. *Current Topics in Medical Mycology* 8:5, 1997.
  37. Rotstein C, Bow EJ, Laverdiere M, *et al.* Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. *Clin Infect Dis* 28:331, 1999.
  38. Malik IA, Moid I, Aziz Z, *et al.* A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. *Am J Med* 105:478, 1998.
  39. Abi-Said D, Anaissie E, Uzun O, *et al.* The epidemiology of hematogenous candidiasis caused by different *Candida* species. *Clin Infect Dis* 24:1122, 1997.
  40. Einsele H, Hebart H, Roller G, Loffler J, Rothenhofer I, Muller CA, Bowden RA, van Burik J, Engelhard D, Kanz L, Schumacher U. Detection and identification of fungal pathogens in blood by using molecular probes. *J Clin Microbiol* 35:1353, 1997.
  41. Walsh TJ, Finberg RW, Arndt C, *et al.* Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. *N Engl J Med* 340:764, 1999.
  42. Maher DW, Lieschke GJ, Green M, *et al.* Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. *Ann Intern Med* 121:492, 1994.
  43. Rowe JM. Treatment of acute myeloid leukemia with cytokines: Effects on duration of neutropenia and response to infections. *Clin Infect Dis* 26:1290, 1998.
  44. Rodriguez-Adrian LJ, Graziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed? *Clin Infect Dis* 26:1270, 1998.
  45. Hughes WT, Armstrong D, Bodey GP, *et al.* 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. *Clin Infect Dis* 25:551, 1997.